Clinical Trial Update: Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating PD-616 in combination with cytarabine for acute myeloid leukemia and myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• PD-616

Snippet

Sponsor: Biosuccess Biotech Co., Ltd. | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: TERMINATED